ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "belimumab and pharmacokinetics"

  • Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

    Richard Dimelow 1, Beulah Ji2 and Herbert Struemper 3, 1GSK, Stevenage, United Kingdom, 2GSK, Uxbridge, Middlesex, United Kingdom, 3GSK, Research Triangle Park

    Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
  • Abstract Number: 756 • 2016 ACR/ARHP Annual Meeting

    Pharmacokinetics and Exposure-Response Relationship of Belimumab Administered Subcutaneously to SLE Patients

    Herbert Struemper1, Mita Thapar2, David Gordon3 and David Roth3, 1Quantitative Clinical Development, PAREXEL, Durham, NC, 2ICON, Marlow, United Kingdom, 3GSK, Philadelphia, PA

    Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
  • Abstract Number: 669 • 2014 ACR/ARHP Annual Meeting

    Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients

    Herbert Struemper1, David Roth2 and David Gordon3, 1GlaxoSmithKline, Research Triangle Park, NC, 2GlaxoSmithKline, Philadelphia, PA, 3Immuno-Inflammation R&D, GlaxoSmithKline, King of Prussia, PA

    Background/Purpose: Monthly (q4w) intravenously (IV) administered belimumab 10 mg/kg is approved for the treatment of adults with active, autoantibody-positive SLE receiving standard therapy. The present…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences